Company news
Starpharma Holdings Limited news in 2020
Starpharma Holdings Limited's news releases, calls and decks from 2020, newest first.
VIRALEZE COVID-19 nasal spray study to commence in January
December 22, 2020
VIRALEZE COVID-19 nasal spray to be ready for market Q1CY21
December 9, 2020
SPL7013 shows potent antiviral activity in RSV
November 18, 2020
Completion of Placement and SPP raises $48.9M in total
October 29, 2020
Starpharma receives $5.7M R&D tax incentive refund
October 20, 2020
Share Purchase Plan offer document
October 6, 2020
Starpharma completes oversubscribed A$45M placement
September 30, 2020
SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
September 14, 2020
Starpharma awarded $1M MRFF funding for COVID-19 spray
September 2, 2020
SPL creates slow release soluble DEP remdesivir nanoparticle
August 31, 2020
SPL7013 nasal spray for COVID19 development update
August 25, 2020
Starpharma signs new DEP partnership with Chase Sun
August 16, 2020
DEP irinotecan boosts immuno-oncology in colon cancer models
June 28, 2020
DEP products showcased at AACR 2020
June 22, 2020
DEP lutetium effective in human prostate cancer model
June 17, 2020
VivaGel BV launched in central and eastern Europe
June 16, 2020
DEP irinotecan phase 2 commences after positive phase 1
May 7, 2020
SPL7013 shows significant activity against coronavirus
April 15, 2020
Quarterly Cashflow and Activity Report
April 7, 2020
Okamoto licenses VivaGel antiviral condom in Asian countries
March 3, 2020
VivaGel BV launched in Asia
February 12, 2020
Starpharma receives US$3M milestone from AstraZeneca
February 10, 2020
Quarterly Cashflow Report
January 28, 2020
Decks in 2020
- Shareholder Meeting (November 2020)
Shareholder meeting · 40 slides · Nov 20, 2020
- Investor Presentation (September 2020)
Investor deck · 44 slides · Sep 30, 2020